Panel Deems Drug-Eluting Stents Safe For On-Label Use, But Wants More Data
This article was originally published in The Gray Sheet
Executive Summary
FDA advisory panel members decided Dec. 7 that the benefit of drug-eluting stent use in FDA-approved indications outweighs the risks. But the panel expressed some skepticism about the strength of data measuring the long-term incidence of blood clots
You may also be interested in...
Confusion Over Anti-Clotting Therapy Hinders Drug-Eluting Stent Rebound
Blanket recommendations for one year of dual antiplatelet therapy for patients who receive drug-eluting stents may be the biggest cloud over the market for the devices, cardiologists suggest
Confusion Over Anti-Clotting Therapy Hinders Drug-Eluting Stent Rebound
Blanket recommendations for one year of dual antiplatelet therapy for patients who receive drug-eluting stents may be the biggest cloud over the market for the devices, cardiologists suggest
Recent Resurgence Of Bare-Metal Stents Will Be Short-Lived, Experts Say
Bare-metal stents will be nearly extinct in five years, according to participants in a panel discussion on future drug-eluting stent utilization at the Cleveland Clinic Medical Innovations Summit on Oct. 2